Multiple motor regions of the brain are underactive during lower limb movements in Parkinson's patients, according to a study.

Published Date: 26 Apr 2023

Parkinson's disease is a prevalent neurodegenerative condition that impairs movement. A person's gait and balance are eventually affected by the disease, which frequently starts with minor hand tremors.

Read Full News

Latest News

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Published Phase 2 Data Highlight Potential of NNZ-2591 in Phelan-McDermid Syndrome Marco Meglio

A phase 2 trial shows NNZ-2591 improves symptoms in children with Phelan-McDermid syndrome, paving the way for a phase 3 study.

Neuroprotective Agent Privosegtor Gains FDA Breakthrough Designation for Optic Neuritis Marco Meglio

Oculis advances Privosegtor, a potential first neuroprotective therapy for optic neuritis, following FDA breakthrough designation and promising trial results.

This Week on NeurologyLive® — January 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Todays Updates

5 Rheumatology Headlines You Missed in December 2025 Victoria Johnson

This rheumatology month in review emphasizes new data and impactful approvals.

Q4 2025 Recap: Rheumatology News and Updates Victoria Johnson

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

Exploring Depressive Symptoms in Low-IQ Youth with Refractory Epilepsy Janelle L Wagner, PhD, Shannon Brothers, PhD, Cortney Wolfe-Christensen, PhD, Louie Pasculli

A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.

FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease Isabella Ciccone, MPH

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

Rituximab Displays Long-Term Effectiveness for Relapsing MS Louie Pasculli

Annette Lenger-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.

NeuroVoices: Nicholas Ashton, PhD, on Advances and Challenges in Alzheimer Disease Biomarkers Nicholas Ashton, PhD, Isabella Ciccone, MPH

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Louie Pasculli

The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.

Todays Updates

5 Rheumatology Headlines You Missed in December 2025 Victoria Johnson

This rheumatology month in review emphasizes new data and impactful approvals.

Q4 2025 Recap: Rheumatology News and Updates Victoria Johnson

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

Exploring Depressive Symptoms in Low-IQ Youth with Refractory Epilepsy Janelle L Wagner, PhD, Shannon Brothers, PhD, Cortney Wolfe-Christensen, PhD, Louie Pasculli

A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.

FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease Isabella Ciccone, MPH

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

Rituximab Displays Long-Term Effectiveness for Relapsing MS Louie Pasculli

Annette Lenger-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.

NeuroVoices: Nicholas Ashton, PhD, on Advances and Challenges in Alzheimer Disease Biomarkers Nicholas Ashton, PhD, Isabella Ciccone, MPH

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Louie Pasculli

The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.

Latest News

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

A phase 2 trial shows NNZ-2591 improves symptoms in children with Phelan-McDermid syndrome, paving the way for a phase 3 study.

Oculis advances Privosegtor, a potential first neuroprotective therapy for optic neuritis, following FDA breakthrough designation and promising trial results.

Here's some of what is coming soon to NeurologyLive® this week.

News All Time

NeurologyLive®: Charting our 2026 Conference Coverage Louie Pasculli

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Fenfluramine Treatment Leads to Long-Term Improved Everyday Executive Functioning in Lennox-Gastaut Syndrome Marco Meglio

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

GLP-1 Liraglutide Displays Effectiveness as Migraine Treatment in Early-Stage Study Louie Pasculli

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Claims Study Highlights Persistence and Reasons for Fenfluramine Use in Lennox-Gastaut Syndrome Marco Meglio

An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.

Semaglutide Linked to Improved Neurological Outcomes in Large Vessel Occlusion Without IV Thrombolysis Marco Meglio

A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.

FDA Action Update, December 2025: Acceptance, Approval, and Clearance Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment Marco Meglio

The newly approved generic product is expected to perform like other high-quality glatiramer acetate generics, with differences confined mainly to the manufacturer and device, not mechanism or dosing.

This Week on NeurologyLive® — January 5, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Uncovering the Complex Relationship Between ADHD and Epilepsy Surgery Outcomes Marco Meglio

Janelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.

AI Model Distinguishes EDSS Subgroup Patterns in Multiple Sclerosis, Study Shows Louie Pasculli

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.

Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026 Marco Meglio

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care.

Clinical Perspectives on Promising Phase 1 Data of CAPN2-Targeting Therapy AMX0114 for ALS Marco Meglio

ALS expert Sabrina Paganoni, MD, PhD, provided follow-up commentary on promising phase 1 data from the LUMINA trial testing Amylyx’s novel agent AMX0114 in patients with early-stage ALS.

A Clinical Review of the 2025 Neuromyelitis Optica Spectrum Disorder Guidelines Benjamin Greenberg, MD, Louie Pasculli

Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.

NeurologyLive® Brain Games: January 4, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on preventative migraine therapies!

Previewing Expected FDA Decisions in Neurology for 2026 Marco Meglio

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

Recommended News For You

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

Study reveals that older women frequently receive an incorrect breast cancer diagnosis.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

The way that miR-377 inhibits cells that cause prostate cancer.

Checking PSA levels too soon after prostate cancer surgery can lead to overtreatment, study suggests

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Recommended Articles For You

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment 

What You Need To Know About Trametinib: A Miracle Cancer Treatment? 

Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

mRNA-based COVID vaccines generate improved responses to immunotherapy

2.

The lack of psychiatrists may be addressed by community workers.

3.

Can Prior Authorization Be Better With Artificial Intelligence?

4.

Safe and acceptable telehealth suicide prevention program.

5.

Childhood cancer survivors face new health problems later in life, study shows

1.

Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor

2.

Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome

3.

Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care

4.

Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role

5.

Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option

2.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

4.

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

5.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot